Profile data is unavailable for this security.
About the company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
- Revenue in USD (TTM)2.41bn
- Net income in USD-271.51m
- Incorporated2013
- Employees1.37k
- LocationSarepta Therapeutics Inc215 First Street, Suite 415CAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 274-4000
- Fax+1 (302) 636-5454
- Websitehttps://www.sarepta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veradermics Inc | 0.00 | -53.81m | 1.62bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 379.59m | -29.23m | 1.63bn | 493.00 | -- | -- | -- | 4.30 | -0.5866 | -0.5866 | 7.49 | -- | 0.3471 | 0.5336 | 5.44 | 769,959.40 | -2.67 | -17.90 | -3.34 | -23.26 | 99.29 | -- | -7.70 | -53.74 | 5.97 | -- | 0.4975 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
| Innoviva Inc | 388.52m | 127.34m | 1.70bn | 127.00 | 17.59 | 1.68 | 10.14 | 4.37 | 1.29 | 1.29 | 4.57 | 13.51 | 0.292 | 1.98 | 4.21 | 3,059,221.00 | 9.57 | 20.06 | 10.66 | 22.10 | 81.50 | -- | 32.78 | 62.81 | 13.33 | 18.15 | 0.2031 | -- | 15.54 | 6.57 | -86.98 | -31.69 | 223.78 | -- |
| ANI Pharmaceuticals Inc | 826.88m | 34.14m | 1.74bn | 897.00 | 47.44 | 3.44 | 13.33 | 2.10 | 1.63 | 1.63 | 40.89 | 22.51 | 0.6135 | 2.18 | 3.68 | 921,828.30 | 3.01 | -2.99 | 3.63 | -3.49 | 61.14 | 58.84 | 4.91 | -6.12 | 2.04 | 3.83 | 0.5508 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Precigen Inc | 6.31m | -425.87m | 1.74bn | 143.00 | -- | 41.66 | -- | 276.49 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.77bn | 382.00 | -- | 37.57 | 129.10 | 7.06 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| Vericel Corp | 258.72m | 13.08m | 1.82bn | 357.00 | 192.09 | 5.65 | 78.45 | 7.03 | 0.1872 | 0.1872 | 4.86 | 6.37 | 0.6133 | 4.00 | 4.75 | 724,697.50 | 3.10 | -1.03 | 3.46 | -1.18 | 73.81 | 69.10 | 5.06 | -1.61 | 4.47 | -- | 0.002 | -- | 20.10 | 15.02 | 425.64 | -- | 89.53 | -- |
| Sarepta Therapeutics Inc | 2.41bn | -271.51m | 1.86bn | 1.37k | -- | 1.41 | -- | 0.7723 | -3.19 | -3.19 | 22.09 | 12.60 | 0.6806 | 0.6977 | 5.81 | 1,759,268.00 | -7.66 | -12.82 | -9.92 | -15.47 | 76.25 | 85.53 | -11.25 | -37.16 | 1.79 | -- | 0.4395 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Aurinia Pharmaceuticals Inc | 265.81m | 77.84m | 1.88bn | 300.00 | 25.37 | 5.13 | 19.28 | 7.06 | 0.561 | 0.561 | 1.88 | 2.77 | 0.4937 | 0.7046 | 7.91 | -- | 14.46 | -18.84 | 16.88 | -20.97 | 88.93 | -- | 29.28 | -72.47 | 5.17 | -- | 0.1645 | -- | 33.97 | 274.78 | 107.37 | -- | 22.71 | -- |
| Organon & Co | 6.30bn | 501.00m | 1.92bn | 10.00k | 3.84 | 2.12 | 2.28 | 0.3049 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 1.93bn | 325.00 | -- | 2.93 | -- | 37.21 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Ultragenyx Pharmaceutical Inc | 672.72m | -575.44m | 1.98bn | 1.29k | -- | -- | -- | 2.94 | -5.84 | -5.84 | 6.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 83.85 | 88.44 | -85.54 | -122.25 | -- | -12.60 | -- | -- | 20.13 | 19.95 | -1.02 | -- | -- | -- |
| Perrigo Company PLC | 4.28bn | -29.20m | 2.00bn | 8.38k | -- | 0.45 | 6.61 | 0.4673 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.07bn | 246.00 | 11.34 | 2.48 | 9.90 | 2.51 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.12bn | 2.48k | 23.17 | 6.37 | 14.83 | 1.45 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
Data as of Feb 13 2026. Currency figures normalised to Sarepta Therapeutics Inc's reporting currency: US Dollar USD
48.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 12.56m | 11.98% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 10.93m | 10.43% |
| AQR Capital Management LLCas of 31 Dec 2025 | 8.10m | 7.74% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 6.60m | 6.30% |
| Erste Asset Management GmbHas of 31 Dec 2025 | 2.73m | 2.60% |
| abrdn, Inc.as of 31 Dec 2025 | 2.25m | 2.15% |
| Two Sigma Investments LPas of 30 Sep 2025 | 2.14m | 2.04% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 2.01m | 1.92% |
| UBS Securities LLCas of 31 Dec 2025 | 2.00m | 1.91% |
| First Trust Advisors LPas of 31 Dec 2025 | 1.99m | 1.90% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
